GeoVax presents on HIV during Washington forum
The forum, which took place on Jan. 27 in Washington, is part of the Washington BioLeaders Forum 2014. GeoVax's Harriet Robinson spoke during a roundtable on emerging technologies and scientific approaches related to vaccines. She presented characteristics distinguishing neutralizing and protective non-neutralizing HIV antibodies.
"The concept of protective non-neutralizing antibody is important for HIV vaccines," Robinson said. "In contrast to neutralizing antibody, that vaccines have failed to elicit, protective non-neutralizing antibody can be elicited by vaccines, and may be particularly effectively elicited by vaccines that display the HIV envelope glycoprotein on virus-like particles -- such as those expressed by the GeoVax GOVX-B11 HIV vaccine."
Robinson also discussed immunogen design that elicits protective non-neutralizing antibodies and highlighted the promise of non-neutralizing antibodies for preventing HIV.
An estimated 500 to 600 people attended the event, including executives from pharma and biotech, regulators, public and private sector investors, payers, analysts and non-governmental organizations.
GeoVax's two component HIV vaccine candidate is compromised of a recombinant DNA and recombinant modified vaccinia Ankara. The vaccine is meant to stimulate both anti-HIV T cell immune responses and anti-HIV antibody responses.